Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.
Also called NCT03206060
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 130 participants
- Registry
-
NCT03206060
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT03206060. Allocation not applicable; no masking; primary purpose treatment. Start 2017-10-10 (actual); primary completion 2030-01-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
- Condition
- Pheochromocytoma
- Condition
- Paraganglioma
- Condition
- Neuroendocrine Tumors
- Condition
- Neuroendocrine Neoplasms
- Intervention (Drug)
- Lu-177-DOTATATE
- Intervention (Drug)
- Ga-68-DOTATATE
- Lead sponsor
- National Cancer Institute (NCI)
Record details
- Record id
cardio:ct-nct03206060- Content hash
88bd5730328a10dbbce9c99a01adb09d1d5cac623104734b971018c4d9d01bed